Inhibrx Biosciences posts updated corporate presentation highlighting INBRX-106 and ozekibart clinical progress

Inhibrx Biosciences posted an updated investor presentation outlining strong INBRX-106 clinical signals and ozekibart registrational results.Key Highlights:Original SEC Filing: Inhibrx Biosciences, Inc. [ INBX ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Consid…